Efficacy of a nicotine mouth spray in smoking cessation: a randomised, double-blind trial
Philip Tønnesen, Hans Lauri, Roland Perfekt, Karl Mann, Anil Batra, Philip Tønnesen, Hans Lauri, Roland Perfekt, Karl Mann, Anil Batra
Abstract
A nicotine mouth spray has advantages over other acute forms of nicotine replacement therapy, such as a faster uptake of nicotine and faster relief of craving. This multicentre, randomised (2:1), double-blind, placebo-controlled efficacy and safety study evaluated self-reported, carbon monoxide-verified continuous abstinence from smoking from week 2 until weeks 6, 24, and 52 in 479 smokers (≥ 1 cigarette per day) who were treated with either active (n=318) or placebo (n=161) spray for 12 weeks and low-intensity counselling at three smoking cessation clinics in Denmark and Germany. Active treatment yielded significantly higher continuous abstinence rates than placebo from week 2 until week 6 (26.1% versus 16.1%; relative success rate (RR) 1.62, 95% CI 1.09-2.41), week 24 (15.7% versus 6.8%; RR 2.30, 95% CI 1.23-4.30), and week 52 (13.8% versus 5.6%; RR 2.48, 95% CI 1.24-4.94). Most adverse events were mild to moderate, and 9.1% of subjects on active spray withdrew due to adverse events, compared to 7.5% on placebo. The overall rate of treatment-related adverse events was 87.4% with active spray versus 71.4% with placebo spray. Nicotine mouth spray delivered significantly higher 6-, 24- and 52-week continuous abstinence rates than placebo.
Trial registration: ClinicalTrials.gov NCT00759304 NCT00766584.
Conflict of interest statement
Statement of Interest
Statements of interest for all authors of this manuscript and for the study itself can be found at www.erj.ersjournals.com/site/misc/statements.xhtml
Figures
References
- Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2008; 1: CD000146.
- Benowitz NL. Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction. Clin Pharmacol Ther 2008; 83: 531–541
- Kraiczi H, Hansson A, Perfekt R. Single-dose pharmacokinetics of nicotine when given with a novel mouth spray for nicotine replacement therapy. Nicotine Tob Res 2011; 13: 1176–1182
- American PsychiatricAssociation(APA) Diagnostic and Statistical Manual of Mental Disorders 4th Edn Text Revision (DSM–IV-TR) Washington, APA, 2000
- Tønnesen P, Paoletti P, Gustavsson G, et al. Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial. Eur Respir J 1999; 13: 238–246
- Tønnesen P. Smoking cessation: how compelling is the evidence? A review. Health Policy 2009; 91: S15–S25
- Fiore MC, Jaén CR, Baker TB, et al. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, US Department of Health and Human Services, Public Health Service, 2008
- Goldstein MG, Niaura R, Follick MJ, et al. Effects of behavioral skills training and schedule of nicotine gum administration on smoking cessation. Am J Psychiatry 1989; 146: 56–60
- Killen JD, Fortmann SP, Newman B, et al. Evaluation of a treatment approach combining nicotine gum with self-guided behavioral treatments for smoking relapse prevention. J Consul Clin Psychol 1990; 58: 85–92
- Doherty K, Kinnunen T, Militello FS, et al. Urges to smoke during the first month of abstinence: relationship to relapse and predictors. Psychopharmacology 1995; 119: 171–178
- Killen JD, Fortmann SP. Craving is associated with smoking relapse: findings from three prospective studies. Exp Clin Psychopharmacol 1997; 5: 137–142
- West RJ, Hajek P, Belcher M. Severity of withdrawal symptoms as a predictor of outcome of an attempt to quit smoking. Psychol Med 1989; 19: 981–985
- Hays JT, Ebbert JO. Adverse effects and tolerability of medications for the treatment of tobacco use and dependence. Drugs 2010; 70: 2357–2372
- Ossip DJ, Abrams SM, Mahoney MC, et al. Adverse effects with use of nicotine replacement therapy among quitline clients. Nicotine Tob Res 2009; 11: 408–417
- Gonzales D, Rennard SI, Nides M, et al. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006; 296: 47–55
- Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006; 296: 56–63
- Tonstad S, Tønnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006; 296: 64–71
Source: PubMed